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Hypertension in children: from screening to primordial 
prevention
Hypertension is a major cause of death and morbidity 
worldwide.1 Until recently, hypertension was rarely 
searched for or diagnosed in children. However, growing 
evidence indicates that elevated blood pressure early 
in life has detrimental lifelong cardiovascular effects, 
raising questions about the potential benefits of 
hypertension screening and prevention starting in 
childhood.2,3
In The Lancet Public Health, Jean Jacques Noubiap and 
colleagues present a systematic review of studies on 
the prevalence of elevated blood pressure in children 
and adolescents in African countries.4 Following a well 
defined, registered, and published research protocol,5 
they identified 51 studies, and did a meta-analysis 
based on the 25 studies that used the same definition 
of elevated blood pressure (ie, systolic or diastolic blood 
pressure at or above the 95th percentile). With data on 
54 196 participants aged 2–19 years, they found large 
variation in the prevalence of elevated blood pressure, 
ranging from 0·2% to 24·8%. The pooled prevalence was 
5·5% (95% CI 4·2–6·9). Between the two recruitment 
periods of the included studies, 1996–2006 and 
2007–2016, the prevalence of elevated blood pressure 
decreased from 8·1% (6·8–9·4) to 5·3% (3·3–7·8).
The prevalence estimates reported by Noubiap and 
colleagues in African countries are roughly comparable 
with estimates from other countries.2,6 The difference in 
the prevalence estimates between studies is explained 
in part by differences in blood pressure measurement 
methods. This is a major (but common) limitation of 
comparisons of blood pressure between populations and 
might limit the validity of pooling of data. Consequently, 
confident conclusions on differences in blood pressure 
between countries are difficult to reach. 
Interestingly, the overall prevalence of elevated 
blood pressure has tended to decrease over the past 
20 years, consistent with findings in many non-African 
countries. Indeed, in a recent systematic review6 of 
studies assessing trends in blood pressure, including 
18 studies, 2 042 470 children from high-income and 
middle-income countries, we noted that although 
the prevalence of overweight or obesity increased 
in 17 studies and decreased in one, blood pressure 
decreased in 13 studies, increased in four, and did not 
change in one.6
What are the clinical and public health implications 
of Noubiap and colleagues’ findings? From a clinical 
point of view, their findings could support the 
promotion of screening. However, several arguments 
exist against systematic screening of hypertension 
in children.2 First, identification of which levels of 
elevated blood pressure require treatment in children 
is difficult. Indeed, the diagnosis of elevated blood 
pressure in children is based on the distribution 
of blood pressure in the population and these 
distributions can differ between countries; diagnosis 
is not risk based. Further, diagnosis of hypertension 
requires measurements of blood pressure at multiple 
visits. In low-resource settings, including in many 
African countries, universal screening of blood 
pressure in children would divert scarce resources..
Second, contrasting with the solid evidence base 
in adults, the absolute risk of cardiovascular disease 
associated with a given level of blood pressure during 
childhood is not known. Because cardiovascular disease 
rarely occurs before the age of 40 or 50 years (ie, the 
absolute risk is low in early life), the absolute benefit of 
lowering of blood pressure in children will inherently 
be low, implying low cost-effectiveness of treatment of 
elevated blood pressure in children. 
Third, the long-term efficacy and safety of anti hyper-
tensive treatment starting in childhood is not known. 
In 2013, the US Preventive Services Task Force stated 
that “current evidence is insufficient to assess the 
balance of benefits and harms of screening for primary 
hypertension in asymptomatic children and adolescents 
to prevent subsequent cardiovascular disease”.3 Targeted 
screening in children at high risk of hypertension and 
early treatment of cases with secondary hypertension 
would probably be preferable.4,7
From a public health viewpoint, several interventions 
to help to prevent the development of elevated blood 
pressure early in life should be considered. A call has 
been made for a lifecourse strategy to prevent and 
manage hypertension across all periods of life.1 Growing 
evidence shows that elevated blood pressure has its 
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roots early in life, from conception through childhood 
and adolescence. Hence, prevention of elevated blood 
pressure in childhood will help to prevent hypertension 
in adulthood and, eventually, reduce the occurrence of 
cardiovascular disease. 
Primordial prevention of hypertension—ie, prevention 
of the development of risk factors such as elevated 
blood pressure8—can be done through improvements 
in maternal nutrition during pregnancy and reductions 
in salt intake, increased consumption of fruit and 
vegetables, avoidance of energy-dense foods, and 
promotion of physical activity among children. 
These strategies also have beneficial effects on other 
cardiometabolic conditions such as obesity, diabetes, 
or dyslipidaemias. Implementation of primordial 
prevention strategies in low-income, middle-income, 
and high-income countries alike is key to maintaining 
lifelong cardiovascular health.2,9
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